[go: up one dir, main page]

SG11202004865SA - Anti-cd40 antibody drug conjugates - Google Patents

Anti-cd40 antibody drug conjugates

Info

Publication number
SG11202004865SA
SG11202004865SA SG11202004865SA SG11202004865SA SG11202004865SA SG 11202004865S A SG11202004865S A SG 11202004865SA SG 11202004865S A SG11202004865S A SG 11202004865SA SG 11202004865S A SG11202004865S A SG 11202004865SA SG 11202004865S A SG11202004865S A SG 11202004865SA
Authority
SG
Singapore
Prior art keywords
drug conjugates
antibody drug
antibody
conjugates
drug
Prior art date
Application number
SG11202004865SA
Inventor
Adrian D Hobson
Jason Z Oh
Michael J Mcpherson
Wendy Waegell
Shaughn H Bryant
Axel Hernandez
Claire L Ihle
Christopher C Marvin
Olivia A Perng
Ling C Santora
Lu Wang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11202004865SA publication Critical patent/SG11202004865SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202004865SA 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates SG11202004865SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593807P 2017-12-01 2017-12-01
US201762595045P 2017-12-05 2017-12-05
PCT/IB2018/059480 WO2019106608A1 (en) 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates

Publications (1)

Publication Number Publication Date
SG11202004865SA true SG11202004865SA (en) 2020-06-29

Family

ID=66663861

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004865SA SG11202004865SA (en) 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates

Country Status (19)

Country Link
US (1) US20220265842A1 (en)
EP (1) EP3716982A4 (en)
JP (1) JP2021504430A (en)
KR (1) KR20200095493A (en)
CN (1) CN111465399A (en)
AU (1) AU2018374633A1 (en)
BR (1) BR112020010691A2 (en)
CA (1) CA3081559A1 (en)
CL (1) CL2020001442A1 (en)
CR (1) CR20200285A (en)
DO (1) DOP2020000119A (en)
EC (1) ECSP20034868A (en)
IL (1) IL274650A (en)
MX (1) MX2020005465A (en)
PE (1) PE20201464A1 (en)
PH (1) PH12020550551A1 (en)
RU (1) RU2020117156A (en)
SG (1) SG11202004865SA (en)
WO (1) WO2019106608A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3908310A1 (en) * 2019-01-11 2021-11-17 Novartis AG Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
US20240189438A1 (en) * 2021-02-04 2024-06-13 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine
TW202304464A (en) 2021-03-23 2023-02-01 美商美國禮來大藥廠 Novel glucocorticoid receptor agonists
TW202304462A (en) 2021-03-23 2023-02-01 美商美國禮來大藥廠 Glucocorticoid receptor agonists
AR125079A1 (en) * 2021-03-23 2023-06-07 Lilly Co Eli CARBOXY-SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS
CN117580849A (en) * 2021-06-24 2024-02-20 江苏先声药业有限公司 Steroid compound, pharmaceutical composition and application thereof
US20250002527A1 (en) * 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
CN118201943A (en) * 2021-09-14 2024-06-14 映恩生物制药(苏州)有限公司 An anti-inflammatory compound and its use
KR20250058769A (en) * 2022-06-16 2025-04-30 애브비 바이오테라퓨틱스 인크. Anti-cd19 antibody drug conjugates
CN120239705A (en) 2022-07-21 2025-07-01 萤火虫生物股份有限公司 Glucocorticoid receptor agonists and conjugates thereof
AU2023347987A1 (en) * 2022-09-22 2025-04-10 Eli Lilly And Company Glucocorticoid receptor agonists
TW202430226A (en) * 2022-12-28 2024-08-01 大陸商上海盛迪醫藥有限公司 Anti-cd40 antibody drug conjugates, preparation methods and pharmaceutical uses thereof
WO2024140903A1 (en) * 2022-12-28 2024-07-04 苏州盛迪亚生物医药有限公司 Composition of cd40-binding molecule and pharmaceutical use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399945T3 (en) * 2007-11-30 2013-04-04 Pfizer Limited Novel glucocorticoid receptor agonists
MX2010007023A (en) * 2007-12-21 2010-09-30 Schering Corp C20-c21 substituted glucocorticoid receptor agonists.
JP6125489B2 (en) * 2011-04-29 2017-05-10 アペクシジェン, インコーポレイテッド Anti-CD40 antibodies and methods of use
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
EP3125943A4 (en) * 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
HRP20200262T1 (en) * 2015-05-29 2020-05-29 Abbvie Inc. Anti-cd40 antibodies and uses thereof
SI3464318T1 (en) * 2016-06-02 2021-07-30 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof

Also Published As

Publication number Publication date
JP2021504430A (en) 2021-02-15
WO2019106608A1 (en) 2019-06-06
CL2020001442A1 (en) 2020-09-11
BR112020010691A2 (en) 2020-11-10
CN111465399A (en) 2020-07-28
PH12020550551A1 (en) 2021-03-22
EP3716982A1 (en) 2020-10-07
ECSP20034868A (en) 2020-08-31
EP3716982A4 (en) 2021-08-11
MX2020005465A (en) 2020-09-07
DOP2020000119A (en) 2020-08-31
IL274650A (en) 2020-06-30
RU2020117156A (en) 2022-01-04
PE20201464A1 (en) 2020-12-17
AU2018374633A1 (en) 2020-05-21
US20220265842A1 (en) 2022-08-25
CR20200285A (en) 2020-09-04
KR20200095493A (en) 2020-08-10
CA3081559A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
IL274650A (en) Anti-cd40 antibody drug conjugates
IL291073A (en) Anti-egfr antibody drug conjugates
IL267834B1 (en) Anti-ccr7 antibody drug conjugates
IL267003A (en) Multi-drug antibody drug conjugates
IL263600A (en) Anti-b7-h3 antibodies and antibody drug conjugates
IL252015A0 (en) Antibody drug conjugates
ZA201705923B (en) Drug conjugates comprising antibodies against claudin 18.2
EP3250238A4 (en) Antibody drug conjugates
IL250189A0 (en) Anti-cdh6 antibody drug conjugates
IL251938A0 (en) Anti-cs1 antibodies and antibody drug conjugates
IL259651A (en) Site specific her2 antibody drug conjugates
IL247936A0 (en) Anti-egfr antibodies and antibody drug conjugates
EP3253212A4 (en) Antibody drug conjugates
SG11201702786RA (en) Glycoengineered antibody drug conjugates
IL287938B2 (en) Antibody drug conjugates
RS61967B1 (en) Met antibody drug conjugates
LU92659B1 (en) Glycooptimized antibody drug conjugates
HK40000483A (en) Anti-egfr antibody drug conjugates
HK40014106A (en) Anti-ccr7 antibody drug conjugates
HK1239709A1 (en) Antibody drug conjugates
HK1233662A1 (en) Anti-cdh6 antibody drug conjugates